pubmed.ncbi.nlm.nih.gov

Strategies for achieving viral hepatitis C micro-elimination in the Netherlands - PubMed

  • ️Mon Jan 01 2018

Review

Strategies for achieving viral hepatitis C micro-elimination in the Netherlands

P A M Kracht et al. Hepatol Med Policy. 2018.

Abstract

The Netherlands is striving to achieve national elimination of the hepatitis C virus (HCV) as one of the first countries worldwide. The favorable HCV epidemiology with both low prevalence and incidence, together with access to care and treatment, present excellent conditions to further build on towards this objective. The Dutch national plan on viral hepatitis, introduced in 2016, defines targets in the HCV healthcare cascade and provides a structural framework for the development of elimination activities. Since many different stakeholders are involved in HCV care in the Netherlands, focus has been placed on micro-elimination initiatives as a pragmatic and efficient approach. These numerous micro-eliminations projects have brought the Netherlands closer to HCV elimination. In the near future, efforts specifically have to be made in order to optimize case-finding strategies and to successfully accomplish the nationwide implementation of the registration and monitoring system of viral hepatitis mono-infections, before this final goal can be reached. The upcoming years will then elucidate if the Dutch' hands on approach has resulted in sufficient progress against HCV and if the Netherlands will lead the way towards nationwide HCV elimination.

Keywords: Hep-CORE, HCV cascade of care; Hepatitis C virus; Micro-elimination.

PubMed Disclaimer

Conflict of interest statement

Not applicable.Not applicable.AH: advisory boards: Abbvie, BMS, Gilead, Janssen, MSD; consultancy: AbbVie; financial support for HCV retrieval project from Abbvie, BMS, Gilead and MSD; JA: advisory boards: Abbvie, BMS, Gilead, Janssen, MSD and ViiV; research grants: AbbVie, BMS; KvE: advisory boards: Abbvie, BMS, Gilead, Janssen-Cilag; Support for HCV patient care path from Abbvie, Gilead, Janssen-Cilag. The other authors declare that they have no competing interest.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1

Dutch HCV care cascade

Fig. 2
Fig. 2

Dutch HCV healthcare stakeholders

Fig. 3
Fig. 3

All 45 hepatitis treatment centers in the Netherlands [–44]

Similar articles

Cited by

References

    1. World Health Organization . Global health sector strategy on viral hepatitis 2016–2021. 2016.
    1. Hogenbirk R, David S, van Steenbergen J, Urbanus A. Meer dan opsporen, Nationaal hepatitisplan: een strategie voor actie. 2016. http://www.rivm.nl/dsresource?objectid=119820d5-d1fe-440f-83cf-ffb7478f0.... Accessed 2 Apr 2018.
    1. Lazarus JV, Wiktor S, Colombo M, Thursz M. EASL international Liver Foundation. Micro-elimination – a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665–666. doi: 10.1016/j.jhep.2017.06.033. - DOI - PubMed
    1. Health Council of the Netherlands. Screening risk groups for hepatitis B and C. The Hague: Health Council of the Netherlands; 2016. https://www.gezondheidsraad.nl/documenten/adviezen/2016/11/01/screening-.... Accessed 2 Apr 2018
    1. Veldhuijzen IK, Conyn-van Spaendonck MAE, Dorigo-Zetsma JW. Seroprevalence of hepatitis B and C in the Dutch population. Infect Bull. 1999;10:182–184.

Publication types

LinkOut - more resources